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Summary
Aim:	The aim of the study was to investigate the correlation between symptoms of overactive bladder (OAB) 
and severity of depressive symptoms in patients treated for depression.
Method:	102 patients (43 males, 59 females) aged 20–67 (M = 46.1±11,3) treated for depression were includ-
ed in this cross-sectional analysis. OAB symptoms were examined with the International Prostate Symptom 
Score (IPSS) and International Consultation on Incontinence Questionnaire Overactive Bladder Module (ICIQ-
OAB). OAB-related quality of life was assessed with the International Consultation on Incontinence Question-
naire Overactive Bladder Quality of Life Module (ICIQ-OABqol). Depressive symptoms were assessed with 
the 17-item Hamilton Depression Rating Scale (HDRS) and Quick Inventory of Depressive Symptomatology 
– Self Report (QIDS-SR).
Results:	Symptoms of OAB assessed with IPSS and ICIQ-OAB were more severe in women than in men. In the 
entire group highest scores in IPSS of assessed OAB symptoms were observed in nocturia (1,53±1,64) followed 
by urinary frequency (1,19±1,48) and lowest in urgency (0,80±1,28). Symptoms of OAB (based on the ICIQ-
OABqol total score) were more bothersome in women (48,74±29,18), than in men (39,18±17,70). In the whole 
group and in women the QIDS-SR total score correlated with the ICIQ-OAB score ( p < 0,05). The total QIDS-SR 
score correlated with the ICIQ-OABqol score in entire group (p < 0,05), in women (p < 0,05) and in men (p < 0,05). 
Patients suffering from at least moderate depression assessed with QIDS-SR had significantly more pronounced 
symptoms of urinary frequency (p = 0,005) and urgency (p = 0,039). A number of other significant (p < 0.05) corre-
lations were observed between the total ICIQ-OAB score and certain items’ scores in the GHQ-30 both in women.
Conclusions:	OAB symptoms are common among patients treated for depressive disorders. There is a cor-
relation between severity of depressive symptoms and OAB. OAB is bothersome and affects the quality of 
life in patients treated for depression. Comorbidity of OAB and depression has clinical significance and that 
should enhance interdisciplinary treatment approaches. Due to limitations of this study, further researches are 
essential to reveal more details of the correlation between OAB and depression.
depression,	OAB,	LUTS,	comorbidity
INTRODUCTION
Overactive Bladder (OAB) refers to, according 
to International Continence Society (ICS) defini-
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tion from 2002, the occurrence of urinary urgen-
cy usually accompanied by pollakiuria (urina-
tion 8 or more times a day, or according to recent 
diagnostic trends such frequency, which is asso-
ciated with annoyance and a decrease in quality 
of life) and nokturia (the complaint that the in-
dividual has to wake at night one or more times 
for voiding and urinating is preceded by a peri-
od of sleep, which also follows), with a possible 
urine incontinence [1].
The above symptoms belong to the lower uri-
nary tract symptoms (LUTS), and more specif-
ically to the LUTS related to urinary accumu-
lation [1]. The diagnosis of OAB, based on col-
lecting the accurate patient’ medical record and 
physical examination, requires exclusion of 
urinary tract infection and other urinary tract 
pathologies. It is a common health problem. 
In multicentre studies carried out up to now, on 
large groups representative of the general popu-
lation, the incidence of OAB was 9-43% in the ex-
amined women and 7-27% in men [2-6]. The in-
cidence of OAB symptoms increases with age, 
both in women and in men [5-6].
In most cases, it is a chronic condition, and in 
some patients the symptoms persist until the 
end of life, despite treatment [7-9]. Treatment 
is currently based mainly on behavioral tech-
niques, lifestyle changes and pharmacotherapy, 
and in case of the absence of their effectiveness, 
invasive methods are also used [9]. The authors 
of the cited Canadian guidelines for the man-
agement of OAB in adults [9] to behavioral tech-
niques include bladder training (BT) and pelvic 
floor muscle therapy (PFMT). Lifestyle changes 
that may have a positive effect on the course of 
OAB include, inter alia, control of the amount 
of consumed fluids and caffeine, change of diet 
and weight loss in the case of obese patients, 
proper treatment of other co-occurring somatic 
diseases, cessation of smoking, as well as the in-
troduction of regular physical effort.
OAB pharmacotherapy is based mainly on an-
timuscarinic drugs (e.g. oxybutynin, tolterodine, 
darifenacin, fesoterodine, solifenacin) and beta-
3 adrenergic receptor agonists (mirabegron). 
The invasive methods of OAB treatment include 
botulinum toxin type A injections into the detru-
sor muscle and sacral neuromodulation (SNM). 
Some patients also use peripheral tibial nerve 
stimulation (PTNS). The long-term occurrence 
of OAB symptoms is associated with a signifi-
cant decrease in quality of life, deterioration of 
physical, sexual, social and sleep quality [10-12].
The work published so far on the gener-
al population indicate the existence of a posi-
tive correlation between OAB and depression. 
In a cross-sectional, multicenter EpiLUTS study 
conducted on a representative group of both 
women and men with annoying OAB symp-
toms reported higher levels of anxiety and de-
pression compared to patients with or without 
OAB symptoms [13-15]. A clinical-control anal-
ysis based on the results of another large Epide-
miology Urinary Incontinence and Comorbidi-
ties (EPIC) study showed a statistically more fre-
quent occurrence of depression in OAB subjects 
than in the control group (148 and 46, respec-
tively, p <0.001) [10]. Also, the National Over-
active Bladder Evaluation (NOBLE) program in 
the United States carried out to assess the prev-
alence and significance of OAB, confirmed a sta-
tistically significant higher incidence of depres-
sion in subjects with OAB compared to healthy 
subjects [5,16]. The relationship between depres-
sion and OAB is bidirectional. The above results 
indicate the coexistence of OAB with depression, 
while other studies have observed new cases of 
OAB in depressed patients [17-21], and some re-
searchers describe new cases of depression in 
patients with OAB [18-19].
Authors of a review paper, describing inter 
alia the studied so far relationship between de-
pression and anxiety with OAB, presented, ac-
cording to the current state of knowledge, possi-
ble explanation of pathomechanisms combining 
OAB with depression [22]. They paid special at-
tention to the low level of health-related quality 
of life, sleep disorders and reduced self-esteem 
of patients with OAB, stress associated with the 
occurrence of depression, as well as with joint 
depression and OAB biological factors associ-
ated with serotonergic and adrenergic activity, 
disturbed by regulation hypothalamic-pituitary-
adrenal pituitary axis, changes in the limbic sys-
tem and perfusion disorders of the cerebral cor-
tex. The use of urological and psychiatric drugs 
also modulates the course of both depressive 
symptoms and OAB. However, the exact nature 
of these dependencies is still largely unknown.
The following study is the first in Poland work 
on the relationship between OAB and depres-
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sion in patients suffering from it. Recently, the 
first Polish work investigating the occurrence of 
LUTS in patients treated for depression [23] was 
published. In this study, a statistically significant 
relationship between depression and LUTS was 
observed. It also confirmed the high frequency 
and significant severity of LUTS symptoms in 
this group of patients. The severity of depres-
sive symptoms correlated positively with the se-
verity of LUTS symptoms examined using the 
QIDS-SR Inventory (Quick Inventory of Depres-
sive Symptomatology – Self Report) and the In-
ternational Prostate Symptom Score (IPSS) re-
spectively. The strong negative impact of the ex-
perienced symptoms of depression and LUTS on 
the quality of life of patients was also confirmed. 
These are observations of high clinical signifi-
cance. This work is a continuation and develop-
ment of these studies on OAB issues.
AIM
The aim of the study was to assess the severity 
of OAB symptoms depending on the severity of 
psychopathological symptoms in patients treat-
ed for depressive disorders.
METHODS
Subjects
The cross-sectional study included patients who 
were 18 years or older and were treated in an out-
patient base in mental health clinic or in psychiat-
ric departments because of depressive disorders. 
The study was approved by the Bioethical Com-
mittee of the Jagiellonian University (no. KBET 
/ 266 / B / 2013). Each participant gave informed 
consent for participation in the study. All subjects 
completed the patient’s clinical observation chart.
DIAGNOSTIC	TOOLS
The International Prostate Symptom Score 
(IPSS), the International Consultation on Incon-
tinence Questionnaire Overactive Bladder Mod-
ule (ICIQ-OAB) and the International Consulta-
tion on Incontinence Questionnaire Overactive 
Bladder Quality of Life Module (ICIQ-OABqol) 
were used to assess the severity of OAB symp-
toms. The IPSS scale was created in 1992 by the 
American Society of Urology [24]. It was used 
repeatedly to assess the severity of LUTS in both 
men and women [23, 25-28]. The scale contains 
7 questions about LUTS (four concern the symp-
toms of the collection phase, three – the empty-
ing phase) and one is related to the quality of 
life. For questions about urological symptoms, 
the examined respond on a scale 0 to 5, indicat-
ing the severity of symptoms, and the overall 
score may be from 0 to 35 points (no symptoms 
to very severe symptoms). The question about 
the quality of life associated with LUTS is rated 
on a scale of 0 to 6 (excellent – unbearable). ICIQ-
OAB and ICIQ-OABqol questionnaires were de-
veloped in the company of International Con-
sultation on Incontinence (ICI) and are used to 
assess the severity of symptoms of bladder hy-
peractivity [29-30] and the specific OAB-related 
quality of life [31]. These are specialized, validat-
ed and ones of the most frequently used ques-
tionnaires on OAB issues. The ICIQ-OAB ques-
tionnaire consists of 8 questions regarding the 
severity of the frequency of pollakiuria, nocturia, 
urgency and urinary incontinence, and the de-
gree of annoyance for each of the symptoms on 
a scale. The ICIQ-OABqol questionnaire consists 
of 25 questions assessing the impact of bladder 
related symptoms on quality of life. Questions 
relate to limitations of the possibility of trave-
ling, feelings of worry, frustration, sleep disor-
ders, nocturia, avoiding social events, worsen-
ing relationships with the loved ones.
The presence and severity of depressive symp-
toms were examined using the Hamilton De-
pression Rating Scale (HDRS) and the Quick In-
ventory of Depressive Symptomatology – Self 
Report (QIDS-SR). HDRS has been used for 
many years to study the severity of depressive 
symptoms [32-33], also in patients with LUTS 
[23, 34-35]. The QIDS-SR self-assessment scale 
is also widely used to assess the severity of de-
pression, has good psychometric properties, is 
equally sensitive and its results correlate with 
the results of the 30-item Inventory of Depres-
sive Symptomatology (IDS) and the 24-item 
Hamilton Rating Scale for Depression [36-37] 
and was recently used in the first Polish work 
examining the relationship between depres-
sion and LUTS [23]. The ranges of the scores in 
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QIDS-SR are defined as follows: remission (0-5 
points), mild depression (6-10 points), moderate 
depression (11-15 points), severe depression (16-
20 points), very severe depression (21-27 points) 
[36]. The General Health Questionnaire (GHQ-
30, a Polish translation by Małyszczak et al.) is 
used for screening the mental health status of 
adults in the general population [38-40].
STATISTICAL	METHODS
In the description of the studied group, the 
arithmetic mean and standard deviation were 
used (SD). Pearson’s correlation was applied as-
sess the relations. Chi2 NW tests and Student’s 
t tests for two independent samples were also 
performed. The deviation was normal (Shapiro-
Wilk test). P scores below than or equal to 0.05 
were considered statistically significant. Statis-
tical analysis was performed using the STATIS-
TICA 12 program (UJ CM license)
RESULTS
102 people were examined: 43 men (42.16%) and 
59 women (57.84%). The characteristics of the 
group are shown in Table 1.
Table	1.	Characteristics	of	the	studied	group
Number of respondents n = 102 (100%)
The average age of the respondents 46.1±11.3 lat
The average BMI value 26.72±5.19 kg/m2
The average duration of previous psychiatric treatment 10.7±8.6 lat
The average number of hospitalizations 2.4±3.5
Sex
Men n = 43 (42.16%)
Women n = 59 (57.84%)
Marital status
Married n = 68 (66.66%)
Divorced n = 9 (8.82%)
In separation n = 3 (2.94%)
Informal relationships n = 5 (4.9%)
Single n = 17 (16.66%)
Education
Primary n = 3 (2.94%)
Secondary n = 35 (34.31%)
Professional n = 11 (10.78%)
Higher n = 53 (51.96%)
Professional status
Employed n = 54 (52.94%)
Pension n = 28 (27.45%)
Unemployment n = 12 (11.76%)
Education n = 5 (4.9%)
Retired n = 3 (2.94%)
Place of residence
Village n = 32 (31.37%)
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City n = 70 (68.63%)
Table	2.	Results	in	HDRS	and	QIDS-SR	scales
Females (N=59 ) Males (N=43 ) All (N=102 )
HDRS (M, SD) 15.33±9.50 15.44±8.27 15.38±8.96
QIDS-SR (M, SD) 14.44±6.16 13.8±6.71 14.17±6.37
The results obtained in the HDRS and QIDS-
SR scales are presented in Table 2.
Evaluation of the severity of symptoms based 
on the results of HDRS and QIDS-SR question-
naires is presented in Table 3.
Table	3.	Degree	of	severity	of	depressive	symptoms	in	HDRS	and	QIDS-SR
Severity HDRS (N. %) QIDS-SR (N. %)
Remission 20 subjects (19.6%) 12 subjects (11.76%)
Mild 24 (23.52%) 18 (17.64%)
Moderate 27 (26.47%) 31 (30.39%)
Heavy 18 (17.64%) 20 (19.6%)
Very heavy 13 (12.74%) 20 (19.6%)
In the next step, IPSS scores were calculated 
(Table 4). The average point value among all 
respondents in the IPSS scale was 8.07 ± 8.76. 
The highest average point value (highest sever-
ity of complaints) among all subjects from all 
IABS-assessed OAB symptoms achieved: noc-
turia (1.53 ± 1.64) and pollakiuria (1.19 ± 1.48), 
and the lowest – the urge pressure (0) 80 ± 1.28). 
In the studied group of men, the highest mean 
point value (the highest severity of complaints) 
among those assessed by the IPSS scale of OAB 
symptoms achieved: nocturia (1.25 ± 1.54) and 
pollakiuria (0.81 ± 1.20), and the lowest urge 
pressure (0, 39 ± 1.04). Similarly, in the group of 
women surveyed, the highest mean point value 
among the OAB symptoms assessed on the IPSS 
scale achieved: nycturia (1.74 ± 1.69) and pollak-
iuria (1.47 ± 1.62), and the lowest – urge pressure 
(1.10 ± 1, 61).
The results of the Chi2 NW test indicated re-
lationships between the severity of each of the 
OAB symptoms assessed and the severity of de-
pressive symptoms in the QIDS-SR scale (remis-
sion or mild depression vs. at least moderate de-
pressive symptoms) in the general population; 
a statistically significant relationship was ob-
served for pollakiuria (p = 0.005) and for urgent 
pressure (p = 0.039).
Table	4.	Severity	of	LUTS	in	IPSS
Severity of LUTS IPSS (N. %)
None or mild 62 subjects (60.78%)
Moderate 31 (30.39%)
Substantial 9 (8.82%)
The results in ICIQ-OAB and ICIQ-OABqol 
scales are presented in Table 5. Higher scores, 
and thus greater annoyance of symptoms of 
bladder hyperactivity were found in the sub-
group of women.
Table	5.	Scores	in	ICIQ-OAB	and	ICIQ-OABqol	scales
Females (N=59 ) Males (N=43 )
ICIQ-OAB (M, SD) 4.01±2.83 2.53±2.40
ICIQ-OABqol (M, SD) 48.74±29.18 39.18±17.70
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Numerous correlations between the severity 
and annoyance of OAB symptoms examined us-
ing the ICIQ-OAB and ICIQ-OABqol scales and 
the severity of depressive symptoms examined 
with the QIDS-SR scale were observed. The sum 
of points in QIDS-SR correlated with the sum 
of points on the ICIQ-OABqol scale for all sub-
jects (r = 0.43, p <0.05), as well as in subgroups 
of women (r = 0.45, p <0.05) ) and men (r = 0.42, 
p <0.05). The similar correlation of the sum of 
points in QIDS-SR was demonstrated with the 
sum of points on the ICIQ-OAB scale in the 
whole group (r = 0.31, p <0.05), and in the sub-
group of women examined (r = 0.33; p < 0.05). 
However, no such correlation was found in 
the subgroup of the studied men. Additional-
ly, in the group of women surveyed with the 
sum of points in the ICIQ-OABqol scale, the sum 
of points in the GHQ-30 scale was correlated 
(r = 0.28, p <0.05). In the subgroup of the studied 
men, the severity of OAB symptoms examined 
with the ICIQ-OAB scale correlated positive-
ly with the results on the QIDS-SR sleep diffi-
culties (r = 0.41, p <0.05). In the group of wom-
en, the intensity of OAB symptoms examined 
using the ICIQ-OAB scale correlated with the 
intensity of the feeling of continuous overload 
(r = 0.33, p <0.05), impediment of mobility and 
activity (r = 0.32, p <0.05) ) and the lack of mean-
ing in life (r = 0.30, p <0.05) assessed using the 
GHQ-30 scale.
DISCUSSION
This study is the first in Poland to analyze the re-
lationship between OAB and depressive symp-
toms. Recently, the first Polish work assessing 
the prevalence of LUTS among people treated 
psychiatrically due to depressive disorders was 
published. Its results indicate a significant prev-
alence and severity of LUTS symptoms in pa-
tients with depression, a significant impact of 
urological symptoms on quality of life, as well 
as a positive correlation of LUTS severity with 
depressive symptoms [23]. In the current study, 
a slightly higher prevalence of OAB symptoms 
was observed in women than in men. This is 
consistent with the results of other studies con-
ducted on the general population [2,4-6,41-42]. 
We also observed a strong negative effect of the 
severity of symptoms of bladder hyperactivity 
on the mental state of the subjects. The burden 
of illness, deterioration of activity and mobili-
ty, the feeling of lack of sense in life described 
by women experiencing OAB should be un-
derstood as factors aggravating depression or 
which may lead to its occurrence. This has al-
ready been described in previous studies [18-19, 
43]. The severity of OAB symptoms and the de-
terioration of quality of life associated with their 
existence correlated positively with the severi-
ty of depressive symptoms assessed using the 
QIDS-SR scale. Greater severity of depressive 
symptoms in patients afflicted with symptoms 
of bladder overactivity and bidirectionality of 
this relationship was postulated earlier [13-16]. 
This is an important, clinically relevant informa-
tion that should lead to coordinated psychiatric 
and urological diagnosis and treatment. Discrep-
ancies observed between the results obtained by 
the respondents in the scales investigating the 
severity of depressive symptoms (QIDS-SR and 
HDRS) may result from the size of the examined 
group and from the nature of the scale (HDRS is 
assessed by the researcher, and QIDS-SR is the 
self-assessment scale). The ICQ-OAB and ICIQ-
OABqol are also self-assessment scales which 
may be related to the correlation of their results 
with those in QIDS-SR. Perhaps patients evalu-
ating themselves describe a greater severity of 
symptoms than a researcher rating them with 
another scale? This may lead to an underestima-
tion of the severity of OAB symptoms by those 
investigating this phenomenon. The authors of 
a review of the OAB literature published a few 
years ago drew attention to the inconsistency in 
assessing the severity of OAB, depending on the 
diagnostic tools used. [44].
In recent years, works investigating the ef-
fect of OAB treatment on co-occurring depres-
sive symptoms have been published. In a pro-
spective study on a group of 112 women treated 
with mirabegron due to OAB, symptomatic im-
provement in OAB was positively correlated with 
a decrease in anxiety symptoms but no correla-
tion was observed for depressive symptoms [45]. 
Another large, retrospective cohort study com-
pared a group of 1952 women with OAB treated 
with antimuscarinics with a group of 9762 wom-
en with OAB who were not treated with anti-
muscarinics [46]. Treatment with antimuscarin-
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ic drugs was associated with more frequent oc-
currence of depression in the group of patients 
with OAB, especially in younger patients. The au-
thors concluded that the use of antimuscarinic 
drugs increases the risk of depression. The use 
of anticholinergic drugs in patients with OAB is 
also associated with a higher risk of falls and frac-
tures, especially in older patients (the so-called 
anticholinergic burden) [47]. In the study of the 
relationship between the use of neuromodulation 
in patients with OAB with comorbid depressive 
and anxiety symptoms, comorbidity of depres-
sion did not reduce the efficiency of neuromod-
ulation in patients with OAB, and the improve-
ment in depressive symptoms correlated with 
a reduction in the severity of OAB symptoms and 
anxiety symptoms [48]. Interesting conclusions 
have been drawn by authors of the study inves-
tigating the relationship between the use of anti-
depressants and the severity of OAB symptoms 
[49]. In this prospective cohort study, a group of 
112 men treated with antidepressants for various 
reasons we compared with a group of 90 healthy 
men who were not treated with antidepressants. 
The incidence and severity of OAB were signif-
icantly higher in the group of men treated with 
antidepressants, in particular venlafaxine. The au-
thors of a systematic review with a meta-analysis 
investigating the association of depression and 
anxiety in OAB did not find statistically signifi-
cant differences between men and women in the 
occurrence and severity of depressive symptoms 
in OAB, but the frequency and severity of anx-
iety symptoms in OAB were significantly high-
er in men than in women [50]. The above exam-
ples point to a number of factors (e.g. the applied 
urological and psychiatric treatment, age, sex, in-
dividual genetic differences) affecting the course 
of OAB, as well as depression. Therefore, it can 
be concluded that the relationship between OAB 
and depression, although undoubtedly clinically 
significant, is complex and has a dynamic char-
acter, depending on many factors.
CONCLUSIONS
Symptoms of OAB among patients treated for 
depressive disorders have high prevalence and 
severity. The most annoying symptoms for all 
patients and also separately for men and wom-
en, were nocturia and pollakiuria. In the pre-
sent study, greater severity of OAB symptoms 
and their greater nuisance were found in wom-
en than in men. A correlation was observed be-
tween the severity of depressive symptoms and 
OAB. In addition, greater severity of depressive 
symptoms correlated with the severity of pollak-
iuria and urgency. OAB is a condition negatively 
affecting the quality of life of patients by imped-
ing mobility and activity, and a sense of lack of 
meaning in life. These are factors that can lead to 
the occurrence or severity of depressive symp-
toms. Co-morbidity of depression and OAB is of 
significant clinical importance, which should re-
sult in further development of interdisciplinary 
therapeutic methods.
This study has limitations inter alia due to 
its cross-sectional nature, the lack of a control 
group, the size of the studied group, and large 
variation in pharmacological treatment. In our 
study, we did not indicate correlation between 
the severity of OAB symptoms and depressive 
symptoms assessed by HDRS. The differences 
between the results in the groups of the studied 
women and men can be explained by the lower 
number of men.
Therefore, in order to better understand the 
nature of the studied relationships between OAB 
symptoms and depressive symptoms, further, 
more complex multicenter cohort and prospec-
tive studies have to be carried out.
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